Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers.

Walfisch A, Al-maawali A, Moretti ME, Nickel C, Koren G.

J Obstet Gynaecol. 2011 Aug;31(6):465-72. doi: 10.3109/01443615.2011.579197. Review.

PMID:
21823839
2.

Major congenital malformations after first-trimester exposure to ACE inhibitors.

Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA.

N Engl J Med. 2006 Jun 8;354(23):2443-51.

3.

Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity.

Schaefer C.

Birth Defects Res A Clin Mol Teratol. 2003 Aug;67(8):591-4.

PMID:
14632309
5.

Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers.

Diav-Citrin O, Shechtman S, Halberstadt Y, Finkel-Pekarsky V, Wajnberg R, Arnon J, Di Gianantonio E, Clementi M, Ornoy A.

Reprod Toxicol. 2011 May;31(4):540-5. doi: 10.1016/j.reprotox.2011.02.008. Epub 2011 Feb 18.

PMID:
21338666
6.
7.
8.

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits.

Pucci M, Sarween N, Knox E, Lipkin G, Martin U.

Expert Rev Clin Pharmacol. 2015 Mar;8(2):221-31. doi: 10.1586/17512433.2015.1005074. Epub 2015 Jan 22. Review.

PMID:
25612630
9.
10.

Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence.

Polifka JE.

Birth Defects Res A Clin Mol Teratol. 2012 Aug;94(8):576-98. doi: 10.1002/bdra.23027. Epub 2012 Jul 17. Review.

PMID:
22807387
11.

Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment.

Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA.

Pharmacoepidemiol Drug Saf. 2003 Dec;12(8):633-46.

PMID:
14762979
12.

ACE inhibitors and major congenital malformations.

Sealey JE, Itskovitz-Eldor J.

N Engl J Med. 2006 Sep 21;355(12):1280-1; author reply 1281. No abstract available.

13.

ACE inhibitors and congenital anomalies.

Friedman JM.

N Engl J Med. 2006 Jun 8;354(23):2498-500. No abstract available.

PMID:
16760451
14.

ACE inhibitors and major congenital malformations.

Scialli AR, Lione A.

N Engl J Med. 2006 Sep 21;355(12):1280; author reply 1281. No abstract available.

PMID:
16998965
15.

First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.

Bérard A, Ramos E, Rey E, Blais L, St-André M, Oraichi D.

Birth Defects Res B Dev Reprod Toxicol. 2007 Feb;80(1):18-27.

PMID:
17187388
16.

[Teratogenic effects of ACE-inhibitors and angiotensin II receptor antagonists].

Sørensen AM, Christensen S, Jonassen TE, Andersen D, Petersen JS.

Ugeskr Laeger. 1998 Mar 2;160(10):1460-4. Review. Danish.

PMID:
9520613
17.

[Inhibition of the renin angiotensin system in pregnancy and risk of fetal malformations].

Lonati C, Morganti A.

Pediatr Med Chir. 2009 May-Jun;31(3):137-9. Italian. No abstract available.

PMID:
19739495
18.

Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy.

Burrows RF, Burrows EA.

Aust N Z J Obstet Gynaecol. 1998 Aug;38(3):306-11. Review.

PMID:
9761159
19.

Angiotensin converting enzyme inhibitors in pregnancy.

Mastrobattista JM.

Semin Perinatol. 1997 Apr;21(2):124-34. Review.

PMID:
9201818
20.

Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.

Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.

J Hypertens. 2008 Jul;26(7):1282-9. doi: 10.1097/HJH.0b013e328306ebe2.

PMID:
18550998

Supplemental Content

Support Center